Compare DCI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCI | CYTK |
|---|---|---|
| Founded | 1915 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 10.7B |
| IPO Year | 2005 | 2004 |
| Metric | DCI | CYTK |
|---|---|---|
| Price | $86.74 | $65.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $99.00 | $89.26 |
| AVG Volume (30 Days) | 582.6K | ★ 1.7M |
| Earning Date | 06-02-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | $13,368,000.00 |
| Revenue This Year | $4.58 | $7.37 |
| Revenue Next Year | $5.18 | $310.19 |
| P/E Ratio | $31.29 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $79.47 | $47.22 |
| 52 Week High | $112.84 | $88.31 |
| Indicator | DCI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.9 billion in revenue in its fiscal 2026.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.